ClinicalTrials.gg
RecruitingNCT07395687Updated Apr 21, 2026

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

A Phase 2 interventional study of UBT251 and Placebo in Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.

Planned enrollment
49th of 166
333 · median 138
Started
2026
with 46 others
Phase 2
13 of 207
1 open now
Primary completion
2027-01
later than 8 of 65 live
Registered
163rd of 207
by date

Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 49th largest by planned enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 8 of the 65 other live ones, and was the 163rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 48 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Obesity by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 333 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female (sex at birth).
  2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported):

    • For Japanese participants: both parents of Japanese descent.
    • For Chinese participants: both parents of Chinese descent.
    • For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
  3. Age at the time of signing the :

    1. For Part A: 18-55 years (both inclusive)
    2. For Part B: 18-65 years (both inclusive)
    3. For Part C: 18-55 years (both inclusive).
  4. at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):

    1. For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
    2. For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
    3. For Part C: 24-34.9 kg/m\^2 (both inclusive)
  5. Considered eligible based on the medical history, physical examination, and the results of vital signs, (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected to study intervention(s) or related products.
  2. Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
  3. Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
333 participants (estimated)

Study arms

  • Experimental
    Part A - UBT251

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Drug: UBT251

  • Placebo comparator
    Part A - placebo

    Participants will receive placebo matched to UBT251 subcutaneously.

    Drug: Placebo

  • Experimental
    Part B - Arm A (UBT251)

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Drug: UBT251

  • Experimental
    Part B - Arm B (UBT251)

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Drug: UBT251

  • Experimental
    Part B - Arm C (UBT251)

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Drug: UBT251

  • Experimental
    Part B - Arm D (UBT251)

    Participants will be randomized to receive 2 dose levels subcutaneously.

    Drug: UBT251

  • Experimental
    Part B - Arm E (UBT251)

    Participants will be randomized to receive a single dose level subcutaneously.

    Drug: UBT251

  • Placebo comparator
    Part B - placebo

    Participants will receive placebo matching one of the UBT251 arms subcutaneously.

    Drug: Placebo

  • Experimental
    Part C - UBT251 dose 1

    Participants will be randomized to receive dose level 1 subcutaneously.

    Drug: UBT251

  • Experimental
    Part C - UBT251 dose 2

    Participants will be randomized to receive dose level 2 subcutaneously.

    Drug: UBT251

  • Experimental
    Part C - UBT251 dose 3

    Participants will be randomized to receive dose level 3 subcutaneously.

    Drug: UBT251

Interventions

  • DrugUBT251

    UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

  • DrugPlacebo

    Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

07

What researchers measure

Primary outcomes

  1. Part A - Number of treatment emergent adverse events (TEAEs)

    Measured as Number of events.

    Time frame: From baseline (week 0) to end of study (week 33)

  2. Part B - Relative change in body weight

    Measured as percentage of body weight.

    Time frame: From baseline (week 0) to end of treatment (week 28)

  3. Part C- AUC; the area under the UBT251 plasma concentration time curve

    Measured as hour\*nanomoles per liter (h\*nmol/L)

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)

Secondary outcomes

  1. Part A - Relative change in body weight

    Measured as percentage of body weight.

    Time frame: From baseline (week 0) to end of treatment (week 28)

  2. Part A - Change in body weight

    Measured as kilogram (kg).

    Time frame: From baseline (week 0) to end of treatment (week 28)

  3. Part A - AUC; the area under the UBT251 plasma concentration-time curve

    Measured as h\*nmol/L

    Time frame: From pre-dose on day 1 to end of study (week 33)

  4. Part A - Cmax; the maximum plasma concentration of UBT251

    Measured as nanomole per liter (nmol/L)

    Time frame: From pre-dose on day 1 to end of study (week 33)

  5. Part B - Change in body weight

    Measured as kg.

    Time frame: From baseline (week 0) to end of treatment (week 28)

  6. Part B - Change in waist circumference

    Measured as centimetre (cm).

    Time frame: From baseline (week 0) to end of treatment (week 28)

  7. Part B - Number of TEAEs

    Measured as number of events

    Time frame: From baseline (week 0) to end of study (week 33)

  8. Part C - Cmax; the maximum plasma concentration of UBT251

    Measured as nmol/L

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)

  9. Part C - Number of treatment-emergent adverse events (TEAEs)

    Measured as number of events.

    Time frame: From pre-dose on Day 1 until completion of the end of study visit (Day 43)

08

Study locations

3 of 3 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2026
First posted
Feb 9, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Jan 14, 2027
CompletionEst.
Feb 18, 2027
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07395687
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Feb 2, 2026
Primary completion
Jan 14, 2027 (estimated)
Completion
Feb 18, 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UBT251

Start the discussion